Table 1 Studies included in systematic review
Authors and year | Study population | Study location | STH studiedb | Diagnostic technique | Primary disease target(s) of chemotherapy | PC regimen | Administration strategy | N roundsc | Ivermectin dosage | Albendazole dosage | Follow-up time after last round | PC coverage |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ame et al. 2022 | Children | Tanzania | A, T, H | Kato Katz | Lymphatic filariasis | Ivermectin, albendazole, praziquantel | ALB PC to SAC + ALB + IVM MDA + ALB + PZQ MDA | 3 | Single dose (200 μg/kg) | Single dose (400 mg) | 36 months | 82% |
Anselmi et al. 2015a | Adults | Ecuador | A, T, H, S | Microscopy (direct stool examination and formol-ether-concentration) | Onchocerciasis | Ivermectin | IVM MDA | 5 | Single dose (150 μg/kg) | Not applicable | 1 month | 89% |
Bah et al. 2019a | Children | Sierra Leone | A, T, H | Kato Katz | Lymphatic filariasis, STH | Ivermectin, albendazole | ALB PC to SAC + ALB + IVM MDA | 5 | Single dose (200 μg/kg) | Single dose (400 mg) | 8 months | 75% |
Echazu et al. 2017a | Community | Argentina | H, S | Five techniques: (1) Microscopy (sedimentation method) (2) Agar plate culture (3) Harada-Mori filter-paper culture (4) Baermann concentration (5) McMaster method | STH | Ivermectin, albendazole | ALB + IVM MDA | 2 | Single dose (200 μg/kg) | Single dose (400 mg) | 17 months | 58% |
Eneanya et al. 2021 arm 1a | Community | Liberia | A, T, H | Kato Katz | Lymphatic filariasis | Ivermectin, albendazole | ALB + IVM MDA (annually) | 3 | Single dose (200 μg/kg) | Single dose (400 mg) | 12 months | 27% |
Eneanya et al. 2021 arm 2a | Community | Liberia | A, T, H | Kato Katz | Lymphatic filariasis | Ivermectin, albendazole | ALB + IVM MDA (semi-annually) | 5 | Single dose (200 μg/kg) | Single dose (400 mg) | 12 months | 35% |
Eneanya et al. 2022 arm 1a | Community | Liberia | A, T, H | Kato Katz | Lymphatic filariasis, onchocerciasis, schistosomiasis, STH | Ivermectin, albendazole, praziquantel | ALB + IVM + PZQ MDA (annually) | 4 | Single dose (200 μg/kg) | Single dose (400 mg) | 24 months | 56% |
Eneanya et al. 2022 arm 2a | Community | Liberia | A, T, H | Kato Katz | Lymphatic filariasis, onchocerciasis, schistosomiasis, STH | Ivermectin, albendazole, praziquantel | ALB + IVM + PZQ MDA (semi-annually) | 7 | Single dose (200 μg/kg) | Single dose (400 mg) | 24 months | 53% |
Gebrezgabiher et al. 2022 | Community | Ethiopia | A, T, H | Microscopy (Ritchie-Frick technique and Kato Katz) | Onchocerciasis | Ivermectin | IVM MDA | 3 | Single dose (150 μg/kg) | Not applicable | 7 months | 88% |
Griswold et al. 2022 | Children | Nigeria | A, T, H | Kato Katz | Schistosomiasis, STH | Ivermectin, albendazole, mebendazole, praziquantel | IVM MDA IVM + ALB MDA PZQ MDA ALB PC to SAC MEB PC to SAC | 5 | Not reported | Not reported | 10 months | 76% |
Heukelbach et al. 2004a | Community | Brazil | A, T, H | Microscopy (sedimentation method) | Parasitic skin diseases | Ivermectin | IVM MDA | 1 | Two doses (200 μg/kg), 10 days apart | Not applicable | 9 months | 83% |
Hurlimann et al. 2018a | Community | Cote d'Ivoire | A, T, H | Kato Katz | Lymphatic filariasis, onchocerciasis, schistosomiasis, STH | Ivermectin, albendazole, praziquantel | IVM + ALB + PZQ MDA | 2 | Not reported | Not reported | 5 months | Not reported |
Knopp et al. 2009 | Children | Zanzibar | A, T, H, S | Kato Katz for A. lumbricoides, T. trichiura, hookworm Baermann for S. stercoralis | Lymphatic filariasis | Ivermectin, albendazole, mebendazole, praziquantel | IVM + ALB MDA ALB + PZQ PC to SAC MEB + PZQ PC to SAC | 16 | Single dose (200 μg/kg) | Single dose (400 mg) | 7 months | Not reported |
Knudson et al. 2012a | Community | Colombia | A, T, S | Microscopy (Ritchie-Frick technique) | Onchocerciasis | Ivermectin | IVM MDA | 23 | Single dose (200 μg/kg) | Not applicable | 4 months | 86% |
Le et al. 2023ba | Children | Timor-Leste | A, T, H, S | Quantitative PCR | Lymphatic filariasis, STH | Ivermectin, diethylcarbamazine citrate, albendazole | IDA MDA | 1 | Single dose (200 μg/kg) | Single dose (400 mg) | 18 months | 76% |
Le et al. 2023a arm 1a | Community | Solomon Islands | A, T, H, S | Quantitative PCR | Scabies | Ivermectin | IVM MDA (1 dose) | 1 | Single dose (200 μg/kg) | Not applicable | 21 months | 93% |
Le et al. 2023a arm 2a | Community | Solomon Islands | A, T, H, S | Quantitative PCR | Scabies | Ivermectin | IVM MDA (2 doses) | 1 | Two doses (150 to 200 μg/kg), 7 to 14 days apart | Not applicable | 21 months | 81% |
Loukouri et al. 2020 arm 1a | Community | Cote d'Ivoire | H | Kato Katz | Lymphatic filariasis | Ivermectin, albendazole | ALB + IVM MDA (annually) | 3 | Single dose (200 μg/kg) | Single dose (400 mg) | 12 months | 65% |
Loukouri et al. 2020 arm 2a | Community | Cote d'Ivoire | H | Kato Katz | Lymphatic filariasis | Ivermectin, albendazole | ALB + IVM MDA (semi-annually) | 5 | Single dose (200 μg/kg) | Single dose (400 mg) | 6 months | 64% |
Marks et al. 2020a | Children | Solomon Islands | S | Serology (bead-based immunoassay testing for antibodies against the recombinant NIE-antigen) | Scabies | Ivermectin, azithromycin | IVM + AZN MDA | 1 | Single dose (200 μg/kg) | Not applicable | 12 months | 91% |
Massa et al. 2009a | Children | Tanzania | A, T, H | Kato Katz | Lymphatic filariasis, Schistosomiasis, STH | Ivermectin, albendazole | ALB + IVM MDA | 1 | Single dose (150 μg/kg) | Single dose (400 mg) | 7 months | 81% |
Moulia-Pelat et al. 1995 | Children | French Polynesia | A, T | Kato Katz | Lymphatic filariasis | Ivermectin, diethylcarbamazine citrate | ID MDA | 1 | Single dose (400 μg/kg) | Not applicable | 1 week | Not reported |
Vargas et al. 2017a | Community | Argentina | A, T, H, S | Serology (NIE-ELISA) | STH | Ivermectin, albendazole | ALB + IVM MDA | 1 | Single dose (200 μg/kg) | Single dose (400 mg) | 17 months | Not reported |
Ziem et al. 2006a | Community | Ghana | H | Kato Katz | Lymphatic filariasis, oesophagostomiasis | Ivermectin, albendazole | ALB + IVM MDA | 1 | Not reported | Single dose (400 mg) | 6 months | 73% |
Ziem et al. 2006ba | Community | Ghana | H | Kato Katz | Lymphatic filariasis, oesophagostomiasis | Ivermectin, albendazole | ALB + IVM MDA | 1 | Not reported | Single dose (400 mg) | 18 months | 75% |